Toxic effects of recombinant tissue plasminogen activator on cultured human corneal endothelial cells

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 4, 2008, Pages 1392-1397

  Yoeruek, Efdal ^a   Spitzer, Martin S ^a   Tatar, Olcay ^a   Biedermann, Tilo ^a   Grisanti, Salvatore ^a   Lüke, Matthias ^a   Bartz Schmidt, Karl U ^a   Szurman, Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3(4,5 DIMETHYLTHIAZOL 2 YL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALTEPLASE; BROMIDE; IODIDE; UNCLASSIFIED DRUG; LIPOCORTIN 5; MEMBRANE PROTEIN; PHOSPHOPROTEIN; RECOMBINANT PROTEIN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TISSUE PLASMINOGEN ACTIVATOR; ZONULA OCCLUDENS 1 PROTEIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DAMAGE; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CYTOTOXICITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; METABOLISM; PATHOLOGY;

ANNEXIN A5; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, CORNEAL; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE PROTEINS; PHOSPHOPROTEINS; RECOMBINANT PROTEINS; TETRAZOLIUM SALTS; THIAZOLES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 45549102061     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1079     Document Type: Article

References (27)

1. Jaffe GJ, Abrams GW, Williams GA, Han DP. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology. 1990;97:184-189.
2. Moon J, Chung S, Myong Y, Chung S, Park C, Baek N, Rhee S. Treatment of postcataract fibrinous membranes with tissue plasminogen activator. Ophthalmology. 1992;99:1256-1259.
3. Tripathi RC, Tripathi BJ, Park JK, et al. Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures. Am J Ophthalmol. 1991;111:247-248.
4. Snyder RW, Sherman MD, Allinson RW. Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty. Am J Ophthalmol. 1990;109:483-484.
5. Heiligenhaus A, Steinmetz B, Lapuente R, et al. Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study. Br J Ophthalmol. 1998;82:810-815.
6. Wedrich A, Menapace R, Ries E, Polzer I. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. J Cataract Refract Surg. 1998;24:575.
7. Siatiri H, Beheshtnezhad AH, Asghari H, Siatiri N, Moghimi S, Piri N. Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery. Br J Ophthalmol. 2005;89:1458-1461.
8. Spitzer MS, Szurman P, Aisenbrey S, Rohrbach JM. Rapid development of band keratopathy of corneal graft associated with treatment with intracameral recombinant tissue plasminogen activator for postoperative fibrin reaction. Eur J Ophthalmol. 2007;17:433-436.
9. Wollensak G, Meyer JH, Loffler KU, Funk J. Band-like keratopathy after treatment of postoperative fibrin reaction with tissue plasminogen activator. Klin Monatsbl Augenheilkd. 1996;209:43-46.
10. Althaus C, Schelle C, Sundmacher R. Acute band-shaped keratopa- thy after intraocular fibrinolysis with recombinant tissue plasminogen activator (rt-PA). Klin Monatsbl Augenheilkd. 1996;209: 318-321.
11. Hrach CJ, Johnson MW, Hassan AS, Lei B, Sieving PA, Elner VM. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol. 2000;118:659-663.
12. Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol. 1990;108:259 -263.
13. Irvine WD, Johnson MW, Hernandez E, Olsen KR. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol. 1991;109:718-722.
14. Chen SN, Yang TC, Ho CL, Kuo YH, Yip Y, Chao AN. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology. 2003;110:704-708.
15. McDermott ML, Edelhauser HF, Hyndiuk RA, Koenig SB. Tissue plasminogen activator and the corneal endothelium. Am JOphthalmol. 1989;108:91-92.
16. Lambrou FH, Snyder RW, Williams GA, Lewandowski M. Treatment of experimental intravitreal fibrin with tissue plasminogen activator. Am J Ophthalmol. 1987;104:619-623.
17. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CP. A novel assay for apoptosis: flow cytometric detection of phospha- tidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth. 1995;184:39-51.
18. Szurman P, Kaczmarek R, Spitzer MS, et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res. 2006;83:584-592.
19. Bourne WM. Cellular changes in transplanted human corneas. Cornea. 2001;20:560-569.
20. Petroutsos G, Savoldelli M, Pouliquen Y. The effect of gentamicin on the corneal endothelium: an experimental study. Cornea. 1990; 9:62-65.
21. Cho KS, Lee EH, Choi JS, Joo CK. Reactive oxygen species induced apoptosis and necrosis in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci. 1999;40:911-919.
22. Dunn RC, Steinleitner AJ, Lambert H. Synergistic effect of intraperitoneally administered calcium channel blockade and recombinant tissue plasminogen activator to prevent adhesion formation in an animal model. Am J Obstet Gynecol. 1991;164(pt 1):1327-1330.
23. Mergler S, Pleyer U. The human corneal endothelium: new insights into electrophysiology and ion channels. Prog Retin Eye Res. 2007;26:359-378.
24. 2+ influx by inhibiting L-type channel activity in cultured human corneal endothelial cells. Exp Eye Res. 2005; 80:285-293.
25. Ozveren F, Eltutar K. Therapeutic application of tissue plasminogen activator for fibrin reaction after cataract surgery. J Cataract Refract Surg. 2004;30:1727-1731.
26. Klais CM, Hattenbach LO, Steinkamp GW, Zubcov AA, Kohnen T. Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children. J Cataract Refract Surg. 1999;25:357-362.
27. Starck T, Hopp L, Held KS, Marouf LM, Yee RW. Low-dose intraocular tissue plasminogen activator treatment for traumatic total hyphema, postcataract, and penetrating keratoplasty fibrinous membranes. J Cataract Refract Surg. 1995;21:219-224.